Conference News
 
                             
                            
                            
                        
 
                             
                            
                            
                        
 
                             
                            
                            
                        
 
                             
                            
                            January 28, 2025
FDA Approves Enhertu for Metastatic, HR-Positive, HER2-Low or -Ultralow Breast Cancer
Conexiant
 
                             
                            
                            
                        Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
 
                             
                            
                            
                        
 
                             
                            
                            
                        
 
                             
                            
                            
                        
 
                             
                            
                            
                        Advertisement
                        Recommendations
Advertisement